Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $8.7 million.

  • Corvus Pharmaceuticals' Cash & Equivalents fell 38.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 38.74%. This contributed to the annual value of $8.7 million for FY2024, which is 30.74% down from last year.
  • As of FY2024, Corvus Pharmaceuticals' Cash & Equivalents stood at $8.7 million, which was down 30.74% from $12.6 million recorded in FY2023.
  • Corvus Pharmaceuticals' Cash & Equivalents' 5-year high stood at $13.2 million during FY2022, with a 5-year trough of $8.7 million in FY2024.
  • Its 3-year average for Cash & Equivalents is $11.5 million, with a median of $12.6 million in 2023.
  • Data for Corvus Pharmaceuticals' Cash & Equivalents shows a maximum YoY plummeted of 30.74% (in 2024) over the last 5 years.
  • Over the past 3 years, Corvus Pharmaceuticals' Cash & Equivalents (Yearly) stood at $13.2 million in 2022, then decreased by 4.10% to $12.6 million in 2023, then tumbled by 30.74% to $8.7 million in 2024.